Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Healthcare Biotechnology
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on... see more

CSE:QNTM - Post Discussion

Quantum BioPharma Ltd > Crystal Research Report
View:
Post by DavidRosenberg on Mar 10, 2022 1:52pm

Crystal Research Report

https://bit.ly/3CEF7Cr
Comment by JAKPUG4LIFE on Mar 10, 2022 2:18pm
Wonder how much this cost investors? By the way is this promotion part of the 6-8 we already have contracts with to promote which cost us investors millions and milillions of dollars including shares on top of that. Dave?
Comment by DavidRosenberg on Mar 10, 2022 3:20pm
All good institutional investors use these reports as a quick guide to analyze their data if they come accross FSD in their research
Comment by JAKPUG4LIFE on Mar 10, 2022 4:01pm
Yes and all good institutional investors will not be looking up FSD with the many failures in the past to go along with zero shareholder value. More wasted money imo
Comment by Mil_Man54 on Mar 10, 2022 4:34pm
You're right Jak....a lot more money wasted....did you actually read the report Rosenberg...especially the section "Risks and Disclosures"..the ENTIRE report is based on information provided by FSD to Crystal Research Associates which did ZERO independant research into FSD.....so all they did was write a report based on the information FSD provided and for that priviledge FSD paid ...more  
Comment by Mil_Man54 on Mar 10, 2022 4:39pm
This made me laugh....the first line in the report describing AD in the report was.... "Mr. Anthony Durkacz is the “D” in FSD"....LMAO....he really is the "D"
Quantum BioPharma Ltd
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities